Materiovigilance in Morocco: The 48-Hour Incident Reporting Rule

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Article 24 of Law No. 84-12 establishes the national materiovigilance system, whose task is to monitor incidents or risks of incidents arising from the use of devices after they have been placed on the market. Article 25 requires the heads of manufacturing, import, export and distribution establishments, together with healthcare professionals who use devices, to report to the competent authority, within 48 hours of becoming aware of them, any incident or risk of incident, as well as any failure or deterioration in quality. Failure to report falls within the heavy penalties of Article 44. Two practical consequences follow immediately. First, the reporting obligation is not limited to harm that has already occurred: a credible risk of an incident starts the same clock. Second, the deadline runs from the moment of awareness, not the moment of occurrence, so the way a company captures complaints internally becomes a compliance variable in its own right. Manufacturers serving the Moroccan market should treat both features as fixed design constraints of their post-market vigilance workflow.

2. Legal basis

Legal instrumentReference / numberPublication dateProvisions
Medical Devices Law (Loi n° 84-12)Dahir n° 1-13-90August 30, 2013Article 24 (national system and its organization); Article 25 (48-hour reporting); Article 44 (penalties for failure to report)

3. Expert insights

Insight 1: the reporting scope covers “an incident or a risk of incident”, not only adverse events that have occurred. Article 24 and Article 25 both use the wording “incident ou risque d’incident”. This means that potential risks are within the reporting scope, and a company cannot decline to report on the ground that no harm has yet been caused. In practice, the safest internal rule is to treat any credible risk signal — a near miss, a malfunction that could plausibly lead to harm, an anomalous trend in complaint data — as reportable unless a documented assessment concludes otherwise.

Insight 2: the reporting subjects cover the entire chain. Article 25 lists four categories of establishment heads — manufacturing, import, export and distribution — plus healthcare professionals who use devices. This is a rare feature of the Moroccan system: healthcare facility staff are placed directly under a reporting duty, which means vigilance information can reach the competent authority through two independent channels, the regulated trade side and the clinical side. Companies should not assume that silence on the distributor side means silence everywhere.

Insight 3: the starting point is “awareness”, not “occurrence”. The provision refers to events “dont ils ont pris connaissance” — of which they have become aware. This settles the attribution question for delayed information flow, but it also obliges companies to define clear internal rules on when awareness is deemed to arise: the moment a salesperson, a customer-service agent or a technical-support engineer receives a complaint may already start the 48-hour clock. Companies distributed across time zones and distributor networks face this issue constantly, since the person who first hears about an event is rarely the person who prepares the report.

Insight 4: quality deterioration must also be reported. The provision places “any failure or deterioration in quality” (toute défaillance ou altération de la qualité) on the same footing as incidents. Even where no clinical consequence has occurred, an abnormality in the product itself is reportable. Manufacturers whose quality systems only classify events by patient harm will need to widen their Moroccan reporting criteria accordingly.

Insight 5: failure to report is expressly listed in Article 44. Article 44 includes “failure to report under Article 25” among the turnover-based penalties: Class I and Class IIA devices face 5% to 7% of turnover (floor of MAD 700,000), and Class IIB and Class III devices face 7% to 10% (floor of MAD 1,000,000). This is one of the most expensive compliance risks of the entire post-market phase, and it attaches to an obligation that is easy to breach accidentally when complaint intake is fragmented across departments or distributors. The fine is calculated on turnover, so even a single missed report on a high-revenue device line can reach the statutory floor very quickly.

Insight 6: the organization and operation of the system are set by regulation. The second paragraph of Article 24 provides that the organization and operation of the national materiovigilance system are determined by regulatory text. Companies need to track that companion text to obtain the concrete requirements for report forms and reporting channels, because the law itself stops at the principle and the deadline. Until that text is issued, the 48-hour deadline and the broad reporting scope of Article 25 remain the operative constraints, and they are already enforceable through the Article 44 penalties.

4. Practical recommendations

  1. Build the 48 hours into a process, not a reminder. Establish a standardized channel from complaint receipt to submission to the competent authority, including translation, review and filing stages, and compress the whole flow to fit within 48 hours.
  2. Define the rule for when “awareness” arises. State in your procedure that the moment sales, customer-service or technical-support staff receive the information counts as company awareness, and set an internal escalation deadline (a practical estimate is no more than 8 hours).
  3. Write the reporting criteria broadly, not narrowly. Explicitly include “risk of incident” and “deterioration in quality” in the internal reporting standard to avoid under-reporting.
  4. Divide reporting duties with the license-holding establishment. The obligation under Article 25 covers both manufacturing and import establishments; the agreement should specify who reports, who assists, and how quickly information is exchanged between the parties. Without that allocation, a complaint received by one party may sit outside the other party’s awareness clock until the 48 hours are nearly spent.
  5. Retain all reporting records. Keep a vigilance log recording the event description, the time of awareness, the time of submission and the receipts, so the file is ready for inspections conducted under Article 38.

5. Verification checklist

  • □ A standard 48-hour reporting procedure with named owners has been established
  • □ Internal rules for determining the moment of “awareness” have been documented
  • □ The reporting standard covers “risk of incident” and “deterioration in quality”
  • □ Reporting duties between the license-holding establishment and the manufacturer have been allocated in the agreement
  • □ A vigilance log exists, recording awareness times and submission receipts
  • □ French-language report templates are ready for use
  • □ The penalty tier for non-reporting under Article 44 has been assessed

Regulatory information verified as of October 30, 2026

Post-market support from GRZAN. GRZAN helps medical device manufacturers and importers serving the Moroccan market manage their post-market compliance obligations, including materiovigilance reporting within statutory deadlines, recall and withdrawal execution, and preparation for inspections and enforcement actions. Our team builds the reporting workflows, vigilance logs and escalation rules described above, and keeps them aligned with the Moroccan regulatory texts. For support with materiovigilance and post-market surveillance in Morocco, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail